Akebia Therapeutics Inc
Company Profile
Business description
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.
Contact
245 First Street
Suite 1400
CambridgeMA02142
USAT: +1 617 871-2098
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2026
Employees
194
Stocks News & Analysis
stocks
Anthropic and OpenAI face commodification threats. Here’s what to watch for
stocks
Berkshire Hathaway: Abel pushes into new territory with Bending Spoons investment
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,944.20 | 31.50 | -0.35% |
| CAC 40 | 7,838.49 | 29.56 | -0.38% |
| DAX 40 | 25,304.42 | 15.35 | -0.06% |
| Dow JONES (US) | 52,446.52 | 480.49 | 0.92% |
| FTSE 100 | 10,733.00 | 31.69 | -0.29% |
| HKSE | 23,867.74 | 319.09 | -1.32% |
| NASDAQ | 26,465.74 | 34.85 | 0.13% |
| Nikkei 225 | 64,075.42 | 841.28 | -1.30% |
| NZX 50 Index | 13,631.69 | 20.38 | -0.15% |
| S&P 500 | 7,715.08 | 24.35 | 0.32% |
| S&P/ASX 200 | 8,816.90 | 28.80 | -0.33% |
| SSE Composite Index | 3,735.37 | 4.45 | 0.12% |